Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Pipeline Review, H2 2017’, provides in depth analysis on Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Toxicology, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease and Musculoskeletal Disorders under development targeting Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects

The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arbor Pharmaceuticals LLC

Bayer AG

BioApex sro

Biogen Inc

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Evgen Pharma Plc

Ixchel Pharma LLC

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

vTv Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Overview

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Companies Involved in Therapeutics Development

Arbor Pharmaceuticals LLC

Bayer AG

BioApex sro

Biogen Inc

C4X Discovery Holdings PLC

Catabasis Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Evgen Pharma Plc

Ixchel Pharma LLC

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

vTv Therapeutics Inc

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drug Profiles

BA-1521 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bardoxolone methyl Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-4001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DH-404 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl fumarate DR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IXC-103 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LGM-2605 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-503 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LH-526 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-132 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MIND-4 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

monosodium luminol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omaveloxolone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-970 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RS-9 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTI-79 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFX-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Nrf2 for Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target NRF2 and BACH1 for Parkinson’s Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NRF-2 for COPD Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Nrf2 for Oncology and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUL-121 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBE-31 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tepilamide fumarate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TFM-735 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCB-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VEDA-1209 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Dormant Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Discontinued Products

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Hardman Research: Funded to the end of Phase II trials

Dec 11, 2017: Reata Pharmaceuticals Presents Interim Phase 1b Data for Omaveloxolone in the Treatment of Unresectable or Metastatic Melanoma

Dec 08, 2017: Novel Compound Restores Immune Response In Patients With Melanoma

Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Phase II Study of Bardoxolone Methyl in Japan at the ASN Kidney Week 2017

Nov 06, 2017: Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting

Nov 03, 2017: Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 23, 2017: Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia

Oct 20, 2017: Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Oct 04, 2017: Evgen Pharma: First European Patent Grant

Sep 13, 2017: Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma

Aug 14, 2017: FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia

Aug 07, 2017: Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome

Aug 02, 2017: Evgen Pharma: SFX-01 data published in Peer Reviewed Journal

Aug 01, 2017: Department Of Defense Report Shows Bach Pharma Drug GVT Reverses Brain Dysfunction

Jul 24, 2017: Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Arbor Pharmaceuticals LLC, H2 2017

Pipeline by Bayer AG, H2 2017

Pipeline by BioApex sro, H2 2017

Pipeline by Biogen Inc, H2 2017

Pipeline by C4X Discovery Holdings PLC, H2 2017

Pipeline by Catabasis Pharmaceuticals Inc, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Evgen Pharma Plc, H2 2017

Pipeline by Ixchel Pharma LLC, H2 2017

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Pipeline by Mochida Pharmaceutical Co Ltd, H2 2017

Pipeline by Reata Pharmaceuticals Inc, H2 2017

Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Pipeline by vTv Therapeutics Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports